Trial Profile

Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD19-anti-CD20-bispecific-chimeric-antigen-receptor-T-cell-therapeutics-Beijing-Doing-Biomedical (Primary)
Indications Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Sponsors Beijing Doing Biomedical

Most Recent Events

19 Jan 2021 Planned End Date changed from 1 Apr 2020 to 1 Mar 2023.
19 Jan 2021 Planned primary completion date changed from 1 Apr 2019 to 1 Mar 2022.
19 Jan 2021 Planned initiation date changed from 1 Oct 2017 to 1 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com